Acumen pharmaceuticals announces first subject dosed in phase 1 study of subcutaneous sabirnetug (acu193) for early alzheimer's disease

Newton, mass., july 29, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (aΒos) in the brain for the treatment of alzheimer's disease (ad), today announced that the first subject has been dosed with a subcutaneous formulation of sabirnetug (acu193) in a phase 1 pharmacokinetic (pk) comparison study. the study plans to compare the pk between subcutaneous and intravenous administrations of sabirnetug in healthy volunteers.
ABOS Ratings Summary
ABOS Quant Ranking